Journal
PHARMACEUTICALS
Volume 15, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/ph15070900
Keywords
pulmonary hypertension; right ventricle failure; MAPK inhibitor; SU5416/hypoxia; inflammation
Categories
Funding
- Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro-FAPERJ [E-26/200.881/2021]
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-CAPES
- Instituto Nacional de Ciencia e Tecnologia de Farmacos e Medicamentos-INCT-INOFAR
Ask authors/readers for more resources
The effects of a newly designed p38 inhibitor, LASSBio-1824, were investigated in experimentally induced pulmonary hypertension. The study showed that LASSBio-1824 normalized vascular resistance by attenuating vessel muscularization and endothelial dysfunction, improving cardiac function and reducing hypertrophy and collagen content in the heart.
Mitogen-activated protein kinase (MAPK) signaling is strongly implicated in cardiovascular remodeling in pulmonary hypertension (PH) and right ventricle (RV) failure. The effects of a newly designed p38 inhibitor, LASSBio-1824, were investigated in experimentally induced PH. Male Wistar rats were exposed to hypoxia and SU5416 (SuHx), and normoxic rats were used as controls. Oral treatment was performed for 14 days with either vehicle or LASSBio-1824 (50 mg/kg). Pulmonary vascular resistance and RV structure and function were assessed by echocardiography and catheterization. Histological, immunohistochemical and Western blot analysis of lung and RV were performed to investigate cardiovascular remodeling and inflammation. Treatment with LASSBio-1824 normalized vascular resistance by attenuating vessel muscularization and endothelial dysfunction. In the heart, treatment decreased RV systolic pressure, hypertrophy and collagen content, improving cardiac function. Protein content of TNF-alpha, iNOS, phosphorylated p38 and caspase-3 were reduced both in lung vessels and RV tissues after treatment and a reduced activation of transcription factor c-fos was found in cardiomyocytes of treated SuHx rats. Therefore, LASSBio-1824 represents a potential candidate for remodeling-targeted treatment of PH.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available